SpliceBio secures $135 Million Series B financing to advance lead program SB-007 in Stargardt disease and expand pipeline of genetic medicines SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, announced the close of a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi […]
Ottimo Pharma, a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, on Thursday announced the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and […]
Congratulations to Renée Aguiar-Lucander, who won the prestigious Executive of the Year Award – Commercial Stage Companies at the Scrip Awards 2024 As the awards celebrated their 20th anniversary, Renée came top from a list of finalists representing the very best in the biotech industry. Renée led the company through clinical development of Tarpeyo (budesonide), […]
